Hims & Hers Health (NYSE:HIMS) Sees Strong Trading Volume - Time to Buy?

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) saw strong trading volume on Friday . 24,581,834 shares traded hands during trading, an increase of 7% from the previous session's volume of 22,898,893 shares.The stock last traded at $51.60 and had previously closed at $46.28.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on HIMS shares. Needham & Company LLC reaffirmed a "hold" rating on shares of Hims & Hers Health in a research report on Monday. Wall Street Zen upgraded shares of Hims & Hers Health from a "hold" rating to a "buy" rating in a report on Sunday, June 15th. Piper Sandler reiterated a "neutral" rating and issued a $39.00 price target (up previously from $35.00) on shares of Hims & Hers Health in a report on Tuesday, May 6th. Citigroup restated a "sell" rating on shares of Hims & Hers Health in a report on Monday. Finally, TD Cowen lowered Hims & Hers Health from a "buy" rating to a "hold" rating and cut their target price for the stock from $44.00 to $30.00 in a research report on Tuesday, April 29th. Three analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $38.31.

Hims & Hers Health Trading Up 8.2%

The business's 50-day simple moving average is $49.65 and its two-hundred day simple moving average is $39.46. The company has a market capitalization of $11.21 billion, a PE ratio of 71.71, a PEG ratio of 1.56 and a beta of 2.09.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The company reported $0.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.12 by $0.08. The company had revenue of $586.01 million for the quarter, compared to the consensus estimate of $535.21 million. Hims & Hers Health had a return on equity of 22.75% and a net margin of 9.24%. Hims & Hers Health's revenue for the quarter was up 110.7% compared to the same quarter last year. During the same period in the previous year, the business earned $0.05 EPS. On average, analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Andrew Dudum sold 36,460 shares of the business's stock in a transaction that occurred on Wednesday, April 16th. The stock was sold at an average price of $28.04, for a total value of $1,022,338.40. Following the completion of the sale, the chief executive officer now directly owns 92,103 shares in the company, valued at approximately $2,582,568.12. The trade was a 28.36% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Oluyemi Okupe sold 11,581 shares of the firm's stock in a transaction on Wednesday, April 2nd. The stock was sold at an average price of $29.26, for a total value of $338,860.06. Following the transaction, the chief financial officer now owns 124,104 shares in the company, valued at $3,631,283.04. This trade represents a 8.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 706,454 shares of company stock valued at $35,220,112 in the last ninety days. Corporate insiders own 13.71% of the company's stock.

Institutional Investors Weigh In On Hims & Hers Health

Institutional investors and hedge funds have recently bought and sold shares of the business. Strs Ohio acquired a new stake in shares of Hims & Hers Health during the 1st quarter worth approximately $1,469,000. Kilter Group LLC increased its position in Hims & Hers Health by 1.0% in the first quarter. Kilter Group LLC now owns 43,989 shares of the company's stock worth $1,300,000 after buying an additional 450 shares during the period. Geneos Wealth Management Inc. bought a new stake in Hims & Hers Health in the first quarter valued at $30,000. Intech Investment Management LLC boosted its holdings in shares of Hims & Hers Health by 74.5% during the first quarter. Intech Investment Management LLC now owns 143,287 shares of the company's stock valued at $4,234,000 after acquiring an additional 61,195 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Hims & Hers Health by 23.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 418,699 shares of the company's stock valued at $12,373,000 after acquiring an additional 78,543 shares during the period. Institutional investors and hedge funds own 63.52% of the company's stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.